Literature DB >> 2400957

Cytotoxicity and antitumor activity of 2',2'-difluorodeoxycytidine (Gemcitabine).

G B Grindey1, L W Hertel, W Plunkett.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2400957     DOI： 10.3109/07357909009017602

Source DB:  PubMed          Journal:  Cancer Invest        ISSN： 0735-7907            Impact factor:   2.176


× No keyword cloud information.
  8 in total

1.  Synthesis and restriction enzyme analysis of oligodeoxyribonucleotides containing the anti-cancer drug 2',2'-difluoro-2'-deoxycytidine.

Authors:  F C Richardson; K K Richardson; J S Kroin; L W Hertel
Journal:  Nucleic Acids Res       Date:  1992-04-11       Impact factor: 16.971

2.  Combination therapy of gemcitabine or oral S-1 with the anti-VEGF monoclonal antibody bevacizumab for pancreatic neuroendocrine carcinoma.

Authors:  Kazuhiko Kasuya; Yuichi Nagakawa; Minako Suzuki; Yoshiaki Suzuki; Bunso Kyo; Satoru Suzuki; Takaaki Matsudo; Takao Itoi; Akihiko Tsuchida; Tatsuya Aoki
Journal:  Exp Ther Med       Date:  2012-01-18       Impact factor: 2.447

3.  A phase I study of topotecan and gemcitabine in advanced solid tumors.

Authors:  Derek S Serna; Tanios Bekaii-Saab; Eric H Kraut
Journal:  Invest New Drugs       Date:  2010-06-25       Impact factor: 3.850

4.  Gemcitabine and vinorelbine combination chemotherapy in anthracycline- and taxane-pretreated advanced breast cancer.

Authors:  Hye Jin Kim; Jin-Soo Kim; Myung-Deok Seo; So-Yeon Oh; Do-Youn Oh; Jee Hyun Kim; Se-Hoon Lee; Dong-Wan Kim; Seock-Ah Im; Tae-You Kim; Dae Seog Heo; Yung-Jue Bang
Journal:  Cancer Res Treat       Date:  2008-06-30       Impact factor: 4.679

Review 5.  Microbiota in pancreatic health and disease: the next frontier in microbiome research.

Authors:  Ryan M Thomas; Christian Jobin
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-12-06       Impact factor: 46.802

6.  A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).

Authors:  S Cascinu; R R Silva; S Barni; R Labianca; L Frontini; E Piazza; G Pancera; P Giordani; L Giuliodori; M A Pessi; V Fusco; G Luporini; R Cellerino; G Catalano
Journal:  Br J Cancer       Date:  1999-07       Impact factor: 7.640

7.  Phase I study of gemcitabine using a once every 2 weeks schedule.

Authors:  J B Vermorken; J P Guastalla; S R Hatty; D E Seitz; B Tanis; C McDaniels; M D Clavel
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  Gemcitabine-induced heparanase promotes aggressiveness of pancreatic cancer cells via activating EGFR signaling.

Authors:  Jin-Wen Song; Ying-Xia Tan; Su-Bo Li; Shi-Kun Zhang; Lu-Ming Wan; Shou-Ping Ji; Hong Zhou; Zhi-Hang Zhou; Feng Gong
Journal:  Oncotarget       Date:  2017-04-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.